Bod Science plots another capital raise as expanded product range set to launch by Steve Jones October 31, 2023November 2, 2023 Bod Science is poised to announce details of another capital raise after a first quarter of […]
Bod eyes opportunities beyond cannabis as Aqua Phase tech passes second bioavailability test by Martin Lane September 27, 2023September 27, 2023
Bod Science eyes new revenue streams after reporting heavy loss by Steve Jones August 30, 2023August 30, 2023
Study delivers ‘new chapter’ for Bod as Aqua Phase tech shows its worth by Steve Jones July 26, 2023July 26, 2023
Bod Science to test drug-delivery tech on psychiatric medication by Steve Jones May 31, 2023May 31, 2023
Hopes rising at Bod Science over commercial prospects for Aqua Phase by Steve Jones May 23, 2023May 25, 2023
Bod Science submits ethics approval for bioavailability study by Steve Jones March 28, 2023April 17, 2023
Bod Science clears stability hurdle for Aqua Phase deal but PK study delayed by Steve Jones March 7, 2023March 7, 2023
Rise of THC flower hits Bod CBD sales as medical revenues fall 29% by Steve Jones February 27, 2023February 27, 2023
Bod spies ‘enormous potential’ of technology acquisition as pressure grows to generate revenue by Steve Jones October 13, 2022October 13, 2022
